Patient-Reported Outcome Measures

Participants self-reported worst CIPN pain intensity for seven consecutive days using a 0–10 numerical rating scale of pain intensity [17, 18]. Several Patient-Reported Outcome Measurement Information System (PROMIS®) short-form instruments [19] were also used to measure pain interference (PROMIS® Pain Interference 4a) [20], sleep-related impairment (PROMIS® Sleep-related Impairment 8a) [21], anxiety (PROMIS® Anxiety 4a) [22], fatigue (PROMIS® Fatigue 4a) [23], depression (PROMIS® Depression 4a) [22], and physical function (PROMIS® Physical Function 4a) [24]. Higher scores on all measures except the Physical Function 4a represented worse symptom severity. CIPN severity was measured using the sensory and motor subscales of the European Organization of Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) [25]. The QLQ-CIPN20 is a twenty-item instrument that measures self-reported severity and functional limitations in sensory (e.g., numbness, tingling, pain), motor (e.g., extremity weakness), and autonomic (e.g., dizziness) domains. Each subscale is scored on a transformed score of 0–100 (worse symptoms) [25]. Both the sensory (α = 0.88) and motor (α = 0.88) subscales have demonstrated sufficient internal consistency reliability [26]. Evidence supports the divergent validity of the sensory and motor subscales based on their ability to discriminate neuropathy severity between participants who had and who had not received neurotoxic chemotherapy [26]. The autonomic subscale was not administered because the subscale demonstrates poor psychometric properties [26, 27].